Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -37.61% is 50% above its 5-year average of -75.11%, near the high end of its 5-year range (-128.71%–-32.82%).
As of the fiscal period ended Tuesday, June 30, 2026. 39.22% above its 12-month average of -61.88%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -37.61%.
RETURN ON INVESTED CAPITAL (ROIC)
-37.61%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-61.88%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-80.59%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-75.11%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+39.22%
CURRENT VS 3Y AVG
+53.32%
CURRENT VS 5Y AVG
+49.92%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.17%
median of 800 covered companies
CURRENT VS SECTOR MEDIAN
-6.95%
vs the sector median at left
X4 Pharmaceuticals, Inc.
Market Cap
$259.85M
Return on Invested Capital (ROIC)
-37.61%
TTM Avg
-61.88%
3Y Avg
-80.59%
5Y Avg
-75.11%
Market Cap
$259.50M
Return on Invested Capital (ROIC)
-28.96%
TTM Avg
-103.16%
3Y Avg
-110.30%
5Y Avg
-171.09%
Market Cap
$258.73M
Return on Invested Capital (ROIC)
-39.76%
TTM Avg
-63.41%
3Y Avg
-63.96%
5Y Avg
-51.83%
Market Cap
$261.31M
Return on Invested Capital (ROIC)
-43.56%
TTM Avg
-66.27%
3Y Avg
-114.94%
5Y Avg
-104.61%
Market Cap
$258.00M
Return on Invested Capital (ROIC)
-89.43%
TTM Avg
-77.88%
3Y Avg
-57.02%
5Y Avg
-48.01%
Market Cap
$263.43M
Return on Invested Capital (ROIC)
-42.92%
TTM Avg
-30.10%
3Y Avg
-80.25%
5Y Avg
-64.52%
Market Cap
$262.88M
Return on Invested Capital (ROIC)
-170.19%
TTM Avg
-56.97%
3Y Avg
-50.85%
5Y Avg
-45.83%
Market Cap
$256.82M
Return on Invested Capital (ROIC)
-3.17%
TTM Avg
-4.70%
3Y Avg
-2.14%
5Y Avg
-2.73%
Market Cap
$264.03M
Return on Invested Capital (ROIC)
-15.00%
TTM Avg
-11.69%
3Y Avg
-3.29%
5Y Avg
-2.92%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| X4 Pharmaceuticals, Inc. (XFOR) | $259.85M | -37.61% | -61.88% | -80.59% | -75.11% |
| Palisade Bio, Inc. (PALI)vs › | $259.50M | -28.96% | -103.16% | -110.30% | -171.09% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $258.73M | -39.76% | -63.41% | -63.96% | -51.83% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $261.31M | -43.56% | -66.27% | -114.94% | -104.61% |
| AC Immune S.A. (ACIU)vs › | $258.00M | -89.43% | -77.88% | -57.02% | -48.01% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $263.43M | -42.92% | -30.10% | -80.25% | -64.52% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $262.88M | -170.19% | -56.97% | -50.85% | -45.83% |
| Anika Therapeutics, Inc. (ANIK)vs › | $256.82M | -3.17% | -4.70% | -2.14% | -2.73% |
| OraSure Technologies, Inc. (OSUR)vs › | $264.03M | -15.00% | -11.69% | -3.29% | -2.92% |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $266.62M | -59.50% | -188.11% | -308.62% | -250.56% |
ROIC
-37.6%
ROE
-58.0%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -37.61% |
| 2026-03-31 | -39.65% |
| 2025-12-31 | -32.82% |
| 2025-09-30 | -70.62% |
| 2025-06-30 | -128.71% |
| 2025-03-31 | -106.68% |
| 2024-12-31 | -124.51% |
| 2024-09-30 | -87.18% |
| 2024-06-30 | -67.22% |
| 2024-03-31 | -128.66% |
| 2023-12-31 | -85.68% |
| 2023-09-30 | -72.43% |
| 2023-06-30 | -65.88% |
| 2023-03-31 | -89.64% |
| 2022-12-31 | -64.87% |
| 2022-09-30 | -81.41% |
| 2022-06-30 | -117.46% |
| 2022-03-31 | -88.80% |
| 2021-12-31 | -71.75% |
| 2021-09-30 | -67.61% |
| 2021-06-30 | -55.25% |
| 2021-03-31 | -45.66% |
| 2020-12-31 | -53.60% |
| 2020-09-30 | -44.07% |
| 2020-06-30 | -37.07% |
| 2020-03-31 | -32.69% |
| 2019-12-31 | -31.42% |
| 2019-09-30 | -43.94% |
| 2019-06-30 | -32.28% |
| 2019-03-31 | -63.96% |
| 2018-12-31 | -781.02% |
| 2018-09-30 | -81.68% |
| 2018-06-30 | -79.87% |
| 2018-03-31 | -63.61% |
| 2017-12-31 | -53.93% |
